Low molecular weight heparin (enoxaparin) versus dextran in the prevention of early occlusion following arterial bypass surgery distal to the groin
2001 (English)In: European Journal of Vascular and Endovascular Surgery, ISSN 1078-5884, E-ISSN 1532-2165, Vol. 21, no 3, 261-265 p.Article in journal (Refereed) Published
AIM: to compare the effect of perioperative dextran and low molecular weight heparin on early graft patency after femorodistal bypass surgery.
DESIGN: prospective randomised multicentre study.
PATIENTS AND METHODS: three hundred and fourteen patients were randomised to dextran 70 or the low molecular weight heparin enoxaparin during and after femorodistal bypass surgery. Patency was evaluated at days 1, 5-7, 30 and 90.
RESULTS: there was no difference in patency at any time point between the two regimens, the crude 90 days patency being 88 and 83%, respectively. There were significantly more patients with heart failure in the dextran group (12.8 vs 0.7%), with other side effects being evenly distributed.
CONCLUSION: dextran 70 and the low molecular weight heparin enoxaparin have the same effect on 90 days femorodistal graft patency, but care must be taken using the dextran to patients with a potential heart insufficiency.
Place, publisher, year, edition, pages
2001. Vol. 21, no 3, 261-265 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-62359DOI: 10.1053/ejvs.2001.1332PubMedID: 11357851OAI: oai:DiVA.org:uu-62359DiVA: diva2:90270